ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EDEN Eden Research Plc

4.25
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.25 4.00 4.50 4.25 4.25 4.25 255,065 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -10.12 22.67M
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.25p. Over the last year, Eden Research shares have traded in a share price range of 3.20p to 12.00p.

Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £22.67 million. Eden Research has a price to earnings ratio (PE ratio) of -10.12.

Eden Research Share Discussion Threads

Showing 17401 to 17419 of 17900 messages
Chat Pages: Latest  704  703  702  701  700  699  698  697  696  695  694  693  Older
DateSubjectAuthorDiscuss
03/3/2024
15:07
T'Owls so she was helpful .lolLinen from flax in upper Wharfedale Mills in Knaresborough on the Nidd.Atb
alchemy
03/3/2024
14:44
Hey Alchemy,I went into a linen shop near the Wharfe, and asked the assistant where I could find the towels.She directed me to a bird sanctuary......
jph
03/3/2024
10:22
Is the billion market phrase the end product or the components we supply ? If the latter we could of course still have turnover of billions depending on our share of the unit prices. Getting enthusiasm for the share has to harmonise with the plausible potential and financial results. A sort of chimneying up the rock face .
alchemy
03/3/2024
08:48
ESG cartel = UN 2030 # dispossessed of men and land #Ruralwomen.


Padma De Pana
·
Ukraine’s agricultural sector ravaged by fighting and Kiev’s press-ganging
The ongoing armed conflict in Ukraine has taken its toll on the country’s agriculture.
While swathes of arable land became inaccessible due to constant fighting, not to mention the risk posed by unexploded ordnance that might be lurking in the fields, the lack of farm workers further complicates the situation.

Seeking to bolster the numbers of its rapidly-dwindling armed forces, Kiev has resorted to press ganging Ukrainians into service, with Bloomberg lamenting that the skills possessed by some of these drafted farmers are often “so specialized that it isn’t easy for women, retirees or others who remain to fill the gap.”

These factors have apparently contributed to a significant decline in Ukraine’s grain production between 2020 and 2024, including corn, wheat, barley and sunflower seeds, the report added, citing data from the US Department of Agriculture.
Such concern for the plight of Ukraine’s agriculture may or may not have something to do with the fact that much of Ukrainian farmland is owned by Western corporations.

“A significant portion of Ukrainian arable land (over 17 million hectares) is owned by Western corporations such as Cargill, DuPont and Monsanto,” the Russian Foreign Ministry said last year.
Having managed to acquire these lands thanks to Kiev lifting a 20-year moratorium on the sale of agricultural land at the IMF's behest, these companies thus “became the main beneficiaries of the Ukrainian grain exports,” the ministry added.

supersonico
02/3/2024
22:30
England has 19 vineyards
alchemy
02/3/2024
11:19
Timbo_Slice

12p would give Eden a market cap of £64 million

Cavendish currently has a target price of 20p, so £107 million market cap

Eden talks about operating in $billion markets with Compound Annual Growth Rates of 15%+

It is not unreasonable for an investor to presume that Eden's target market cap is much higher than £107 million. That Cavendish number takes no account of the impending insecticide deal or its label extension (see Placing RNS) or the label extension(s) to Ecovelex or Powdery Mildew label extensions applied for on Mevalone, but not yet received e.g. France.

I believe Eden considers itself to be at the forefront or a leader in some of the work it is doing. That could be supported by, for example, Ecovelex and Corteva's recognition of the same.

Furthermore, Eden self-declares that it is "Our vision is to be a global leader in sustainable crop protection through the development of bioactive products enabled or enhanced by our novel encapsulation and delivery technologies."


You cannot make such statements and operate in $billion markets and be pleased with a £107 million market cap. That makes no sense on any level for a company in the process of 'global expansion'.

Given the above, Eden needs to sell this vision more directly to investors to mobilise the share price and get belief into the Company, visible in its share price, so that investors truly believe in the Company, their investment and that the value of their £1 today is near guaranteed to be worth significantly more in the near future.

If not, we need to talk about being a participant in £million markets and reset both ambition and expectation.

I'm pretty sure the former statement sits better and more accurately, so Eden needs to communicate this more effectively so it it properly understood and so that such commentary and written words are not throw away, meaningless statements.

investingisatrickygame
02/3/2024
11:14
Will you two stop flirting with each other. (And lol at £20m net worth!). You really do believe anything written down don’t you?
kittybiscuits
02/3/2024
10:04
Dear Neuts,*Please use to your greatest advantage (snip)*I have one username. I am the only person who uses it to post. I am a very long-term investor in EDEN. I am significantly offside. I believe EDEN are in the best position they have even been in (by chance or design). If the stock goes to zero, it does not change my life in any way. For someone who has stated they have their own research resource, over £20million net worth, and a wife, you have a lot of time to post on this board. I would be very happy if you exposed any wrongdoing or illegal activity. I believe EDEN trades over 12 pence this year. Have a great weekend. KumBo.
timbo_slice
01/3/2024
18:23
You really are a clown Tom.
kittybiscuits
01/3/2024
16:50
Whilst we wait. I watched my young male cat stalk puzzlingly then decide that a pheasant like the chickens he had earlier encountered was interesting but not going to be part of his diet.
supersonico
01/3/2024
15:27
Whilst we wait. I saw curlew oystercatchers lapwings on the Yorkshire moors last week. Kingfisher on the river Wharfe . Guests saw an owl. Nuthatch etc
alchemy
01/3/2024
14:36
1) - Completely relevant

2) - Firstly, you have no idea if they are buying or not, and even if they are (or aren't), it's of no concern to you as you don't even own any stock in Eden (By your own admission).

As I have said many times, you are just an internet troll, full of lies and bull. You probably spend all your time playing warcraft so a troll is quite apt for you.

kittybiscuits
01/3/2024
13:17
Re the last several posts by the insane ramping liar -

1) Irrelevant to the (non-existent) prospects of this constock

2) So why hasn't the c*nt been buying? ;D ;D

Biggest eeejits on AIM are to be found here......

neutralpov
29/2/2024
19:35
The Bayer Protection Act
February 29, 2024 0

By Pete Kennedy

Another chapter in the Great Poisoning is currently unfolding in the Iowa Legislature with a bill that could be a preview of what’s to come in many state Houses across the country. Senate File 2392 (SF 2392) would provide virtual immunity to pesticide manufacturers whose products have caused injury and illness; the bill has passed out of committee and is now up for a vote of the full Senate. The bill has been called the equivalent of the 1986 federal law, the National Childhood Vaccine Injury Act, which created immunity for vaccine manufacturers from lawsuits for injuries their products caused.

SF 2392 provides, in part, that:

“[F]or any pesticide registered with the United States environmental protection agency [EPA]…, the label approved by the United States environmental protection agency in registering the pesticide, or a label consistent with the most recent human health assessment performed under the federal Insecticide, Fungicide and Rodenticide Act, or a label consistent with the United States environmental protection agency carcinogenicity classification for the pesticide…shall be sufficient to satisfy any requirement for a warning regarding health or safety….”;

The bill amounts to a “Bayer Protection Act.” As of 2022, Bayer had settled over 1,000 lawsuits and paid around $11 billion in damages from glyphosate-based products such as Roundup; as of that time, there were 30,000 pending lawsuits against Bayer. There are many studies showing glyphosate does cause certain types of cancer. In 2015, the International Agency for Research on Cancer (IARC) classified glyphosate as a probable carcinogen; EPA has not made a similar finding. Bayer purchased Monsanto in 2018, and evidence in the court cases against Bayer proves that Monsanto employees and EPA officials colluded to distort the truth that glyphosate causes cancer.

The overwhelming majority of successful pesticide injury lawsuits are won under “failure to warn” claims, such as the failure to warn of a product causing cancer. With the collusion between the pesticide industry and EPA, the EPA-approved labels on products such as Roundup don’t come close to accurately describing the health risks those products present. Products containing glyphosate do not have a warning about cancer on the label. Reliance on EPA-approved labels provides inadequate protection.

Passage of SF 2392 into law would make it almost impossible for there to be a successful personal injury lawsuit against a company that had an EPA-registered pesticide. Another chemical giant that stands to benefit from SF 2392 is ChemChina (formerly Syngenta), the manufacturer of the herbicide Paraquat; there are thousands with Parkinson’s disease involved in litigation over Paraquat being the cause of their illness, with the number of litigants steadily growing. Costs for injuries or illness caused by pesticide exposure can last a lifetime, but if the bill passes into law, companies with deep pockets like Bayer and ChemChina (each has over $100 billion in assets) would not have to pay damages. Iowa citizens would be denied their right to obtain compensation for injuries pesticide manufacturers have caused.

This is not the first time that pesticide companies have used a state-by-state strategy to maintain their profits. After losing a case in 1991 when the U.S. Supreme Court upheld the right of local governments to restrict pesticide use, subsequently, the industry successfully lobbied 43 states to enact laws preempting local governments. A 2022 U.S. Supreme Court decision rejected an attempt by Bayer to overturn large damage awards for injuries glyphosate caused. Legislation similar to SF 2392 has been introduced in three other states this legislative session; one such bill in Idaho has already been defeated (see Senate Bill 1245).

Beyond Pesticides and the Pesticide Action Network are good resources for staying informed on whether a “Bayer Protection Act” is before your state legislature or Congress.

This article was originally written by the author as an action alert and published by the Weston A. Price Foundation (WAPF) on February 26, 2024: “Tell Your Senator to Vote NO on SF 2392: Hold Pesticide Manufacturers Accountable for Injury.”

supersonico
29/2/2024
19:05
OTC Markets Group @OTCMarkets
·
In a new episode of our #OTCQB podcast, @edenresearch
(OTCQB: $EDNSF) CEO Sean Smith discusses the company's expansion into the US . Eden Research is a UK based company focused on sustainable biopesticides and plastic-free encapsulation technology.

OTCQB Podcast

supersonico
29/2/2024
16:12
Neuts
Sub 5p average here, bought recently. Well in profit. Happy

money never sleeps
29/2/2024
14:45
MNS

Ecovelex has been RNS'd as €40 million per annum for Europe alone. Eden needs to start talking about the big opportunities that lie before them as it is these opportunities that justify global expansion

investingisatrickygame
29/2/2024
14:22
Mevalone

Expected newsflow for 2024:

- UK approval
- Approval in other central EU countries
- UK Distributor appointment pending

Current market opportunity in euros (based on full label / targets):
- 3.0m Southern EU
- 0.3 ROW
- 2.8 US

= 6.1m euros out of Total addressable market of 205m euros ('future' addressable market of 582m euros).

Eden's current target forecasts require 3% market penetration.
Future target, 14.7m euros based upon 2.5% market penetration.

money never sleeps
29/2/2024
10:25
Super, not only that, but tell investors what value, in management's opinion, that adds to the share price. What in management's opinion, should the share price be when that deal is done?

Cavendish says 20p now, without that deal, so let's start talking north of 20p for what will be the biggest deal in the company's history.

You have to look investable and most if not all, view that on ROI. Are my 6p shares in the market worth 20p today? Cavendish says so, so let's support and emphasise that current value.

investingisatrickygame
Chat Pages: Latest  704  703  702  701  700  699  698  697  696  695  694  693  Older

Your Recent History

Delayed Upgrade Clock